ViCentra develops and manufactures Kaleido, an insulin patch pump positioned as the smallest, lightest and most precise pump in its class. The system integrates with Diabeloop’s DBLG1 and DBLG2 hybrid closed-loop algorithms to deliver automated insulin therapy, and it is styled with premium materials and interchangeable aluminium shells in ten colours to resemble consumer technology rather than a traditional medical device. ViCentra currently commercialises Kaleido in parts of Europe and is expanding production capacity to meet strong demand. With fresh capital in hand, the company plans to bolster commercial execution in Germany, the Netherlands and France, while accelerating regulatory and operational preparations to enter the U.S. market. Management has set a goal to nearly triple its European user base by the end of 2026. Financially, ViCentra has secured a total of $98 million in Series D funding, including an $85 million tranche closed in September 2025 and a $13 million extension announced in the latest round.

Total raised

$183M

Funding rounds

4

Latest round

Series D

Latest activity

Jan 2026